genotype

Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies
Dorothea Bankwitz, Akash Bahai, Maurice Labuhn, Mandy Doepke, Corinne Ginkel, Tanvi Khera, Daniel Todt, Luisa J Ströh, Leona Dold, Florian Klein, Frank Klawonn, Thomas Krey, Patrick Behrendt, Markus Cornberg, Alice C McHardy, Thomas Pietschmann

Gut Dec 2020, gutjnl-2020-321190; DOI: 10.1136/gutjnl-2020-321190
Naturally occurring 5′ preS1 deletions markedly enhance replication and infectivity of HBV genotype B and genotype C
Jing Li, Jisu Li, Shiqi Chen, Quan Yuan, Jing Zhang, Jingwen Wu, Qirong Jiang, Qianru Wang, Ning-Shao Xia, Jiming Zhang, Shuping Tong

Gut Jun 2020, gutjnl-2019-320096; DOI: 10.1136/gutjnl-2019-320096
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
Gamal Shiha, Gamal Esmat, Mohamed Hassany, Reham Soliman, Mohamed Elbasiony, Rabab Fouad, Aisha Elsharkawy, Radi Hammad, Wael Abdel-Razek, Talaat Zakareya, Kathryn Kersey, Benedetta Massetto, Anu Osinusi, Sophia Lu, Diana M Brainard, John G McHutchison, Imam Waked, Wahid Doss

Gut Apr 2019, 68 (4) 721-728; DOI: 10.1136/gutjnl-2017-315906
In vitro and in silico evidence against a significant effect of the SPINK1 c.194G>A variant on pre-mRNA splicing
Hao Wu, Arnaud Boulling, David N Cooper, Zhao-Shen Li, Zhuan Liao, Jian-Min Chen, Claude Férec

Gut Dec 2017, 66 (12) 2195-2196; DOI: 10.1136/gutjnl-2017-313948
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
Tania M Welzel, David R Nelson, Giuseppe Morelli, Adrian Di Bisceglie, Rajender K Reddy, Alexander Kuo, Joseph K Lim, Jama Darling, Paul Pockros, Joseph S Galati, Lynn M Frazier, Saleh Alqahtani, Mark S Sulkowski, Monika Vainorius, Lucy Akushevich, Michael W Fried, Stefan Zeuzem

Gut Oct 2017, 66 (10) 1844-1852; DOI: 10.1136/gutjnl-2016-311609
Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses
Amélie Menard, Sarah Aherfi, Saadia Mokhtari, Catherine Dhiver, Isabelle Ravaux, Hervé Tissot-Dupont, Line Meddeb, Philippe Brouqui, Andreas Stein, Philippe Colson

Gut Oct 2017, 66 (10) 1868-1869; DOI: 10.1136/gutjnl-2016-313431
Reply: ‘More viral mutants, less HBsAg clearance? One size may not fit all'
Alex Thompson, Stephen Locarnini, Peter Revill

Gut Aug 2017, 66 (8) 1534-1535; DOI: 10.1136/gutjnl-2016-313287
PWE-003 Mdm2 t309g polymorphism and risk of colorectal cancer
N Aggarwal, ND Donald, S Malik, SS Selvendran, M McPhail, KJ Monahan

Gut Jul 2017, 66 (Suppl 2) A126-A127; DOI: 10.1136/gutjnl-2017-314472.248
PWE-002 The association of low penetrance variants in dna repair genes with colorectal cancer: a systematic review and meta-analysis
N Aggarwal, ND Donald, S Malik, SS Selvendran, M McPhail, KJ Monahan

Gut Jul 2017, 66 (Suppl 2) A126; DOI: 10.1136/gutjnl-2017-314472.247
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver
Ibrahim M Sayed, Lieven Verhoye, Laurence Cocquerel, Florence Abravanel, Lander Foquet, Claire Montpellier, Yannick Debing, Ali Farhoudi, Czeslaw Wychowski, Jean Dubuisson, Geert Leroux-Roels, Johan Neyts, Jacques Izopet, Thomas Michiels, Philip Meuleman

Gut May 2017, 66 (5) 920-929; DOI: 10.1136/gutjnl-2015-311109

Main menu

genotype

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

genotype

Pages